Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion.
### Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Maintenance of healing of erosive esophagitis
* Reduction of risk of NSAID-associated gastric ulcers in patients needing continuous NSAID treatment
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
### Adult Dosing
* **Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **NSAID-Associated Gastric Ulcers:** 40 mg orally once daily. Duration is typically up to 8 weeks.
* **Hypersecretory Conditions:** 40 mg orally or intravenously twice daily initially, may be increased as needed. Doses up to 240 mg daily have been used.
### Pediatric Dosing
* **Erosive Esophagitis (12 to 17 years):** 40 mg orally once daily for up to 8 weeks.
* **Erosive Esophagitis (5 to 11 years):** 20 mg orally once daily for up to 8 weeks. For more severe esophagitis or if initial therapy is ineffective, may increase to 40 mg once daily.
* *Dosing in younger children (< 5 years) is not well established and typically relies on weight-based recommendations or expert consultation.*
### Dose Adjustments
No dose adjustment is generally required for hepatic or renal impairment, though caution may be advised in severe hepatic impairment.
### Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
### Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
Long-term use (over 1 year) may be associated with an increased risk of:
* Fractures (hip, wrist, spine)
* Clostridium difficile infection
* Vitamin B12 deficiency
* Hypomagnesemia (can be serious)
### Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, mycophenolate mofetil, certain antiretrovirals. PPIs can decrease absorption.
* **Methotrexate:** PPIs may increase levels of methotrexate.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel (though clinical significance is debated and often managed by alternatives).
### Monitoring
* Monitor for signs and symptoms of fractures, C. difficile infection, B12 deficiency, and hypomagnesemia, especially with prolonged use or in patients with risk factors.
* Monitor magnesium levels in patients on long-term therapy or those receiving concomitant medications that may cause hypomagnesemia (e.g., diuretics).
### Clinical Pearls
* Oral pantoprazole is generally administered 30-60 minutes before a meal.
* Intravenous administration may be used when oral therapy is not feasible. Reconstitute and dilute according to manufacturer instructions; infusion should be over at least 15 minutes.
* Consider the risks associated with long-term PPI use; use the lowest effective dose for the shortest duration necessary.
* Black box warning regarding potential increased risk of fracture, C. difficile, and hypomagnesemia with long-term PPI use.
***
*Disclaimer: This information is intended for clinical decision-making and does not replace a thorough review of the current prescribing information, local protocols, or consultation with a medical professional. Always verify the most up-to-date dosing, indications, and safety information.*
